Table 9. Major Characteristics of Sixty-one Single Arm Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
| Author/ Years/ Country | Participating Institutions |
Study Period | Design | Level of evidence | Number of CRC PC | HIPEC |
|---|---|---|---|---|---|---|
| Passot/ 2012/ France [21] |
1 | 1991-2010 | retrospective | III | 120 (120/120) | MMC (10 mg/ml, total dose 40-60mg) for 90 min at 46-48 °C using closed abdomen technique. MMC (0.7 mg/kg) + CPT-11 (100 mg/m2) for 90 min at 44-46 °C using closed abdomen technique. MMC (30-50 mg/m2) with or without DDP (50-100 mg/m2) for 60-120 min at 41-42.5 °C using coliseum technique or closed abdomen technique. L-OHP (360-460 mg/m2) with or without CPT-11 (100-200 mg/m2) with or without intravenous 5-FU and LV for 30 min at 43°C using coliseum technique or closed abdomen technique. |
| Passot/ 2016/ France [104] |
1 | 1989-2015 | retrospective | III | 342 (342/1,125) | Idem (Passot/ 2012/ France [21]) |
| Pilati/ 2003/ Italy [71] |
1 | 1995-2001 | retrospective | III | 46 (46/46) | MMC (3.3 mg/m2/L) with or without DDP (25 mg/m2/L) for 90 min at 41.2-42.1 °C using coliseum technique or closed abdomen technique. |
| Prada-Villaverde/ 2014/ Spain [72] | 15 | 2000-2011 | retrospective | III | 539 (539/539) | MMC or L-OHP for 30-120 min at 40-43°C using coliseum or closed abdomen technique. |
| Quenet/ 2011/ France [73] | 2 | 1998-2007 2002-2007 |
prospective | IIb | 146 (146/146) | L-OHP (460 mg/m2) with intravenous 5-FU (400 mg/m2) and LV (20 mg/m2) for 30 min at 42-45 °C using coliseum technique. L-OHP (300 mg/m2) with CPT-11 (200 mg/m2) with intravenous 5-FU (400 mg/m2) and LV (20 mg/m2) for 30 min at 42-45 °C using coliseum technique. |
| Rivard/ 2014/ Canada [74] | 1 | 2003-2011 | retrospective | III | 68 (68/68) | NR |
| Rodt/ 2013/ Denmark [75] | 1 | 2006-2011 | retrospective | III | 19 (19/35) | NR |
| Shen/ 2004/ America [20] |
1 | 1991-2002 | retrospective | III | 77 (77/77) | MMC (total dose 30 mg) for 60-120 min at 38.5-43 °C using closed abdomen technique. |
| Shen/ 2008/ America [76] |
1 | 1992-2005 | retrospective | III | 55 (55/150) | MMC (total dose 30 mg) for 60-120 min at 38.5-43 °C using closed abdomen technique. |
| Simkens GA/ 2015/ Netherlands [102] | 1 | 2007-2013 | retrospective | III | 133 (133/133) | MMC (35 mg/m2) for 90 min at 41.1 °C using open-coliseum technique. |
| Swellengrebel/ 2009/ Netherlands [77] | 1 | 1999-2005 | retrospective | III | 92 (92/92) | MMC (35 mg/m2) for 90 min at 41-42 °C using coliseum technique. |
Note: MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; NR: not reported